Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Gaboxadol in Adult Primary Insomnia
NCT00094627Phase 3Completed
- Sponsor
- Lundbeck
- Start
- Nov 2004
- Modality
- Small Molecules
01
Overview
Phase 3, randomised, double-blind trial of gaboxadol in Insomnia (3 arms), sponsored by Lundbeck. Primary endpoints: Wake After Sleep Onset at 2 days and Latency to Persistent Sleep at 2 days. Started Nov 2004; status: completed.
02
Drugs
gaboxadol
03
Conditions
Insomnia
Beyond the preview
Go deeper on NCT00094627.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00094627.